MIM
KRTX

MetLife Investment Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

MetLife Investment Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,000
Closed -$633K – 2838
2023
Q4 		$633K Sell
2,000
-28
-1% -$5.44K ﹤0.01% 1552
2023
Q3 		$343K Hold
2,028
– – ﹤0.01% 1858
2023
Q2 		$440K Sell
2,028
-15,011
-88% -$3.22M ﹤0.01% 1780
2023
Q1 		$3.09M Buy
17,039
+1,227
+8% +$235K 0.02% 719
2022
Q4 		$3.11M Hold
15,812
– – 0.02% 713
2022
Q3 		$3.56M Buy
15,812
+2,146
+16% +$434K 0.03% 591
2022
Q2 		$1.73M Buy
13,666
+1,367
+11% +$157K 0.01% 952
2022
Q1 		$1.56M Buy
12,299
+4,297
+54% +$484K 0.01% 1098
2021
Q4 		$1.05M Hold
8,002
– – 0.01% 1111
2021
Q3 		$979K Hold
8,002
– – 0.01% 1126
2021
Q2 		$912K Buy
8,002
+1,987
+33% +$232K 0.01% 1222
2021
Q1 		$723K Sell
6,015
-899
-13% -$102K 0.01% 1310
2020
Q4 		$702K Hold
6,914
– – 0.01% 1297
2020
Q3 		$535K Hold
6,914
– – 0.01% 1335
2020
Q2 		$771K Buy
6,914
+2,279
+49% +$198K 0.01% 1143
2020
Q1 		$334K Buy
4,635
+2,361
+104% +$202K ﹤0.01% 1435
2019
Q4 		$171K Buy
+2,274
New +$99.6K ﹤0.01% 2061

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

MetLife Investment Management's KRTX Position: Q1 2024 in Review

MetLife Investment Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 2,000 shares — an estimated $633K sold.

MetLife Investment Management first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $3.56M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • MetLife Investment Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • MetLife Investment Management sold 2,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $633K.
  • MetLife Investment Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
  • MetLife Investment Management's Karuna Therapeutics, Inc. Common Stock position peaked at $3.56M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on MetLife Investment Management's 13F filing for Q1 2024, filed 14 May 2024.